FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310923058> ?p ?o ?g. }

• W4310923058 endingPage "100223" @default.
• W4310923058 startingPage "100223" @default.
• W4310923058 abstract "Blockade of the PD-1 pathway is the mainstay for the first-line (1L) treatment of patients (pts) with advanced NSCLC without targetable oncogenic alterations. Cemiplimab is a PD-1 inhibitor and has improved overall survival (OS) and progression-free survival (PFS) vs chemotherapy in 1L advanced NSCLC patients with high PD-L1 expression (PD-L1 ≥50%) who are without driver mutations based on the EMPOWER-Lung 1 study. Cemiplimab was subsequently licensed as monotherapy in this front line pt population by the FDA (Feb 2021) and EMA (May 2021) based on results from EMPOWER-Lung 1. Currently, there are no prospective data on the effectiveness and safety of cemiplimab in advanced NSCLC within routine clinical practice setting. Such data could provide additional evidence to guide treatment and optimal use as per the licensed indication, including in patients that could have been excluded or not typically included in clinical trials. Therefore, CEMI-LUNG (NCT05363319) is a pragmatic, prospective, noninterventional, observational cohort study that aims to address these data gaps. Pts with advanced NSCLC who are initiating a licensed cemiplimab-based regimen as part of their routine clinical practice are eligible. Study visits will follow the standard-of-care schedule and data will be collected every 3 months while on treatment and every 6 months for 36 months following treatment discontinuation (maximum study duration, 72 months) until death, loss to follow-up, study withdrawal or end of study period, whichever occurs first. The study plans to enrol ∼300 pts across 30 European sites. Decisions regarding treatment will be made by the treating physician in accordance with local clinical practice. The primary objective is to assess overall survival. Secondary objectives are to describe objective response rate, time to response, time to first subsequent anti-NSCLC treatment, duration of response, PFS, and the incidence and severity of adverse events. Three interim analyses are planned in addition to the final analysis. This study is open for enrolment. NCT05363319. Editorial writing support was provided by Sameen Yousaf, PhD, of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc., and Sanofi. Sanofi and Regeneron Pharmaceuticals, Inc. Sanofi and Regeneron Pharmaceuticals, Inc." @default.
• W4310923058 created "2022-12-21" @default.
• W4310923058 creator A5011356186 @default.
• W4310923058 creator A5021423429 @default.
• W4310923058 creator A5022064705 @default.
• W4310923058 creator A5030546786 @default.
• W4310923058 creator A5065522363 @default.
• W4310923058 creator A5068647940 @default.
• W4310923058 creator A5074293980 @default.
• W4310923058 creator A5082310325 @default.
• W4310923058 date "2022-12-01" @default.
• W4310923058 modified "2023-09-30" @default.
• W4310923058 title "119TiP An observational study to assess the effectiveness and safety of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC) in routine clinical practice within Europe (CEMI-LUNG)" @default.
• W4310923058 doi "https://doi.org/10.1016/j.iotech.2022.100223" @default.
• W4310923058 hasPublicationYear "2022" @default.
• W4310923058 type Work @default.
• W4310923058 citedByCount "0" @default.
• W4310923058 crossrefType "journal-article" @default.
• W4310923058 hasAuthorship W4310923058A5011356186 @default.
• W4310923058 hasAuthorship W4310923058A5021423429 @default.
• W4310923058 hasAuthorship W4310923058A5022064705 @default.
• W4310923058 hasAuthorship W4310923058A5030546786 @default.
• W4310923058 hasAuthorship W4310923058A5065522363 @default.
• W4310923058 hasAuthorship W4310923058A5068647940 @default.
• W4310923058 hasAuthorship W4310923058A5074293980 @default.
• W4310923058 hasAuthorship W4310923058A5082310325 @default.
• W4310923058 hasBestOaLocation W43109230581 @default.
• W4310923058 hasConcept C126322002 @default.
• W4310923058 hasConcept C143998085 @default.
• W4310923058 hasConcept C23131810 @default.
• W4310923058 hasConcept C2775832928 @default.
• W4310923058 hasConcept C2776256026 @default.
• W4310923058 hasConcept C2778715236 @default.
• W4310923058 hasConcept C2781413609 @default.
• W4310923058 hasConcept C535046627 @default.
• W4310923058 hasConcept C71924100 @default.
• W4310923058 hasConceptScore W4310923058C126322002 @default.
• W4310923058 hasConceptScore W4310923058C143998085 @default.
• W4310923058 hasConceptScore W4310923058C23131810 @default.
• W4310923058 hasConceptScore W4310923058C2775832928 @default.
• W4310923058 hasConceptScore W4310923058C2776256026 @default.
• W4310923058 hasConceptScore W4310923058C2778715236 @default.
• W4310923058 hasConceptScore W4310923058C2781413609 @default.
• W4310923058 hasConceptScore W4310923058C535046627 @default.
• W4310923058 hasConceptScore W4310923058C71924100 @default.
• W4310923058 hasLocation W43109230581 @default.
• W4310923058 hasOpenAccess W4310923058 @default.
• W4310923058 hasPrimaryLocation W43109230581 @default.
• W4310923058 hasRelatedWork W1967103478 @default.
• W4310923058 hasRelatedWork W2032912323 @default.
• W4310923058 hasRelatedWork W2085208618 @default.
• W4310923058 hasRelatedWork W2372561159 @default.
• W4310923058 hasRelatedWork W2390152934 @default.
• W4310923058 hasRelatedWork W2466043692 @default.
• W4310923058 hasRelatedWork W2535269429 @default.
• W4310923058 hasRelatedWork W2765980456 @default.
• W4310923058 hasRelatedWork W2976382042 @default.
• W4310923058 hasRelatedWork W4254658616 @default.
• W4310923058 hasVolume "16" @default.
• W4310923058 isParatext "false" @default.
• W4310923058 isRetracted "false" @default.
• W4310923058 workType "article" @default.